Absolutely. The end point for these trials would not be whether they're protective, which would take a long time and a lot of people in the trials. The end point could simply be how well the mix-and-match strategy elicits a very robust immuno-response relative to not using a mix-and-match strategy; that is, going in with two doses of the RNA vaccines or two doses of the viral vector vaccines. Those are quick trials that could be done over a period of about a month or so to assess this. I think there are some—
On February 22nd, 2021. See this statement in context.